A Digital Environment for Multi-modal Relational Management, Representation, and Analysis of Cancer Clinical Studies
Authors:
- Ferran Cardoso RodriguezFRFerran Cardoso Rodriguez
- Xixuan ZhuXZXixuan Zhu
- Eugene F. SchusterESEugene F. Schuster
- Lucy KilburnLKLucy Kilburn
- Holly ToveyHTHolly Tovey
- Aude EspinasseAEAude Espinasse
- Ruth SardinhaRSRuth Sardinha
- Tom LundTLTom Lund
- Alistair RingARAlistair Ring
- Manuel Salto-TellezManuel Salto-Tellez
- Maggie Chon U CheangMCMaggie Chon U Cheang
Preprint
Abstract
Biologically rich clinical trials generate heterogeneous datasets whose relationships and clinical context must be preserved. Here we present the POETIC-AI environment, a trial-centric digital environment for integrating, analysing, and exploring multimodal data from POETIC, a randomised phase III trial of peri-operative aromatase inhibition in hormone receptor-positive breast cancer ( NCT02338310 ). We implemented a graph-based ontology linking patients, treatments, sampling timepoints, specimens, assays, images, spatial regions, and derived measurements; and designed code-based and graphical analytical workflows. Using proliferation as a test case, we reproduced POETIC’s established reduction in Ki67% and examined variation underlying sample-level measurements. In response-enriched cohorts, mean Ki67% decreased while relative variation among pathologist-assessed fields increased (paired Wilcoxon, P < 0.0001). Pathologist-assessed Ki67% correlated strongly with an 18-gene transcriptomic proliferation signature ( r = 0.834), and both decreased significantly during treatment (P < 0.0001). An annotation-free pixel-wise Ki67 H-score showed weaker correlations and a similar but non-significant reduction ( r = 0.327-0.472; P = 0.15), highlighting differences between tumour-focused and whole-section image quantification. Digital pathology and spatial molecular measurements remained linked to their source images and annotated tissue regions, enabling exploration within their morphological and spatial context using bespoke interactive applications. POETIC-AI demonstrates how the structure, provenance, and tissue context of evolving multimodal clinical-trial data can be preserved within a connected research environment, supporting reproducible analyses and the laying the groundwork for future development of biologically interpretable computational biomarkers.Keywords
Funding Information
- Cancer Research UK (CRUK/07/015)
- Cancer Research UK (C1491–A15955)
This publication has 11 references indexed in Scilit:
- Molecular profiling of aromatase inhibitor sensitive and resistant ER+HER2- postmenopausal breast cancersNature Communications, 2023
- Multimodal biomedical AINature Medicine, 2022
- HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancerEBioMedicine, 2022
- Big data: Historic advances and emerging trends in biomedical researchCurrent Research in Biotechnology, 2022
- Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working GroupJNCI: Journal of the National Cancer Institute, 2020
- Cellpose: a generalist algorithm for cellular segmentationNature Methods, 2020
- Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trialThe Lancet Oncology, 2020
- The FAIR Guiding Principles for scientific data management and stewardshipScientific Data, 2016
- Development and verification of the PAM50-based Prosigna breast cancer gene signature assayBMC Medical Genomics, 2015
- Short-Term Changes in Ki-67 during Neoadjuvant Treatment of Primary Breast Cancer with Anastrozole or Tamoxifen Alone or Combined Correlate with Recurrence-Free SurvivalClinical Cancer Research, 2005